» Articles » PMID: 10954628

Primary Superficial Bladder Cancer Risk Groups According to Progression, Mortality and Recurrence

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2000 Aug 23
PMID 10954628
Citations 111
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We identified risk groups in primary superficial bladder cancer according to progression, mortality and recurrence rates.

Materials And Methods: The prognostic factors of progression, mortality and recurrence were identified by multivariate analysis in a cohort of 1,529 patients with primary superficial bladder cancer. Risk groups were designed by combining the relative risk of these prognostic factors. We performed survival analysis of progression, tumor mortality and recurrence by risk group using the Kaplan-Meier method. Relative risk in each group was calculated by Cox regression. We present timetables of progression, mortality and recurrence by risk group.

Results: Risk groups were classified as low-grade 1 stage Ta disease and a single grade 1 stage T1 tumor, intermediate-multiple grade 1 stage T1 tumors, grade 2 stage Ta disease and a single grade 2 stage T1 tumor, and high-multiple grade 2 stage T1 tumors, grade 3 stages Ta and T1 disease, and any stage disease associated with carcinoma in situ. Survival analysis of progression, mortality and recurrence revealed a statistically significant difference among the 3 risk groups. The rates of recurrence, progression and mortality were 37%, 0% and 0% in the low, 45%, 1.8% and 0.73% in the intermediate, and 54%, 15% and 9.5% in the high risk group, respectively. The relative risks of recurrence, progression and mortality in the low versus the intermediate and high risk groups were 1.37, 2.84 and 1, and 1.87, 24.76 and 14.69, respectively.

Conclusions: Risk group classification based on prognostic factors defines progression, mortality and recurrence rates in primary superficial bladder cancer. It may be useful for designing treatment and followup strategies.

Citing Articles

Identification and construction of prognostic clusters and risk-prognosis model based on aging-immune related genes in bladder cancer.

Cao N, Cheng F, Zhou J, Liu N Discov Oncol. 2024; 15(1):742.

PMID: 39630308 PMC: 11618553. DOI: 10.1007/s12672-024-01655-0.


Cholesterol Metabolism and Urinary System Tumors.

Yang S, Ye Z, Ning J, Wang P, Zhou X, Li W Biomedicines. 2024; 12(8).

PMID: 39200296 PMC: 11351655. DOI: 10.3390/biomedicines12081832.


Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.

Hannouneh Z, Hijazi A, Alsaleem A, Hami S, Kheyrbek N, Tanous F Cancer Med. 2023; 12(24):21944-21968.

PMID: 38037752 PMC: 10757155. DOI: 10.1002/cam4.6768.


Cost of bladder cancer in Lebanon before and after the economic collapse: a probabilistic modeling study.

Raad E, Helou S, Hage K, Daou M, El Helou E Int J Equity Health. 2023; 22(1):77.

PMID: 37131206 PMC: 10152790. DOI: 10.1186/s12939-023-01885-8.


STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancer.

Athans S, Krishnan N, Ramakrishnan S, Gomez E, Lage-Vickers S, Rak M Cancer Res Commun. 2022; 2(10):1129-1143.

PMID: 36275363 PMC: 9583756. DOI: 10.1158/2767-9764.crc-22-0155.